$25,000,000. (I) For support for the development of non-opioid pharmacological therapies as alternatives for opioids, for each of fiscal years 2020 through 2029, $3,500,000. (J) For carrying out section 714A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 379d–3a